248 related articles for article (PubMed ID: 24281389)
1. COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina.
Arredondo J; Lara M; Ng F; Gochez DA; Lee DC; Logia SP; Nguyen J; Maselli RA
Hum Genet; 2014 May; 133(5):599-616. PubMed ID: 24281389
[TBL] [Abstract][Full Text] [Related]
2. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the C-terminal domain of ColQ in endplate acetylcholinesterase deficiency compromise ColQ-MuSK interaction.
Nakata T; Ito M; Azuma Y; Otsuka K; Noguchi Y; Komaki H; Okumura A; Shiraishi K; Masuda A; Natsume J; Kojima S; Ohno K
Hum Mutat; 2013 Jul; 34(7):997-1004. PubMed ID: 23553736
[TBL] [Abstract][Full Text] [Related]
4. Developmental consequences of the ColQ/MuSK interactions.
Karmouch J; Dobbertin A; Sigoillot S; Legay C
Chem Biol Interact; 2013 Mar; 203(1):287-91. PubMed ID: 23089045
[TBL] [Abstract][Full Text] [Related]
5. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction.
Cartaud A; Strochlic L; Guerra M; Blanchard B; Lambergeon M; Krejci E; Cartaud J; Legay C
J Cell Biol; 2004 May; 165(4):505-15. PubMed ID: 15159418
[TBL] [Abstract][Full Text] [Related]
6. Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency.
Sigoillot SM; Bourgeois F; Karmouch J; Molgó J; Dobbertin A; Chevalier C; Houlgatte R; Léger J; Legay C
FASEB J; 2016 Jun; 30(6):2382-99. PubMed ID: 26993635
[TBL] [Abstract][Full Text] [Related]
7. Targeting acetylcholinesterase to the neuromuscular synapse.
Rotundo RL; Rossi SG; Kimbell LM; Ruiz C; Marrero E
Chem Biol Interact; 2005 Dec; 157-158():15-21. PubMed ID: 16289417
[TBL] [Abstract][Full Text] [Related]
8. Collagen Q is a key player for developing rational therapy for congenital myasthenia and for dissecting the mechanisms of anti-MuSK myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Ohtsuka K
J Mol Neurosci; 2014 Jul; 53(3):359-61. PubMed ID: 24234034
[TBL] [Abstract][Full Text] [Related]
9. C-terminal and heparin-binding domains of collagenic tail subunit are both essential for anchoring acetylcholinesterase at the synapse.
Kimbell LM; Ohno K; Engel AG; Rotundo RL
J Biol Chem; 2004 Mar; 279(12):10997-1005. PubMed ID: 14702351
[TBL] [Abstract][Full Text] [Related]
10. Protein-anchoring therapy to target extracellular matrix proteins to their physiological destinations.
Ito M; Ohno K
Matrix Biol; 2018 Aug; 68-69():628-636. PubMed ID: 29475025
[TBL] [Abstract][Full Text] [Related]
11. Synaptic basal lamina-associated congenital myasthenic syndromes.
Maselli RA; Arredondo J; Ferns MJ; Wollmann RL
Ann N Y Acad Sci; 2012 Dec; 1275():36-48. PubMed ID: 23278576
[TBL] [Abstract][Full Text] [Related]
12. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme.
Ohno K; Brengman J; Tsujino A; Engel AG
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9654-9. PubMed ID: 9689136
[TBL] [Abstract][Full Text] [Related]
13. Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction.
Ito M; Suzuki Y; Okada T; Fukudome T; Yoshimura T; Masuda A; Takeda S; Krejci E; Ohno K
Mol Ther; 2012 Jul; 20(7):1384-92. PubMed ID: 22371845
[TBL] [Abstract][Full Text] [Related]
14. Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.
Otsuka K; Ito M; Ohkawara B; Masuda A; Kawakami Y; Sahashi K; Nishida H; Mabuchi N; Takano A; Engel AG; Ohno K
Sci Rep; 2015 Sep; 5():13928. PubMed ID: 26355076
[TBL] [Abstract][Full Text] [Related]
15. [Congenital myasthenic syndromes].
Ohno K
Rinsho Shinkeigaku; 2012; 52(11):1159-61. PubMed ID: 23196549
[TBL] [Abstract][Full Text] [Related]
16. The collagen ColQ binds to LRP4 and regulates the activation of the Muscle-Specific Kinase-LRP4 receptor complex by agrin at the neuromuscular junction.
Uyen Dao TM; Barbeau S; Messéant J; Della-Gaspera B; Bouceba T; Semprez F; Legay C; Dobbertin A
J Biol Chem; 2023 Aug; 299(8):104962. PubMed ID: 37356721
[TBL] [Abstract][Full Text] [Related]
17. Three novel COLQ mutations and variation of phenotypic expressivity due to G240X.
Shapira YA; Sadeh ME; Bergtraum MP; Tsujino A; Ohno K; Shen XM; Brengman J; Edwardson S; Matoth I; Engel AG
Neurology; 2002 Feb; 58(4):603-9. PubMed ID: 11865139
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family.
Matlik HN; Milhem RM; Saadeldin IY; Al-Jaibeji HS; Al-Gazali L; Ali BR
Pediatr Neurol; 2014 Jul; 51(1):165-9. PubMed ID: 24938146
[TBL] [Abstract][Full Text] [Related]
19. Congenital myasthenic syndromes with acetylcholinesterase deficiency, the pathophysiological mechanisms.
Legay C
Ann N Y Acad Sci; 2018 Feb; 1413(1):104-110. PubMed ID: 29405353
[TBL] [Abstract][Full Text] [Related]
20. ColQ controls postsynaptic differentiation at the neuromuscular junction.
Sigoillot SM; Bourgeois F; Lambergeon M; Strochlic L; Legay C
J Neurosci; 2010 Jan; 30(1):13-23. PubMed ID: 20053883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
